Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as VP-102
VP-102 and applicator · 1 trial · 8 indications
Proportion of subjects exhibiting complete clearance of all treatable warts (baseline and new) at the Study Day 84 EOT Visit.
| Arm | Type | Description |
|---|---|---|
| Part A: VP-102 2 hour-Active | ACTIVE_COMPARATOR | For part A, VP-102 will be applied for 2 hours and removed. If selected as a dose regimen for Part B VP-102 will be applied for 2 hours and removed.In both parts, VP-102 is applied every 21 days for 4 treatments. |
| Part A: VP-102 6-hour Active | ACTIVE_COMPARATOR | For part A, VP-102 will be applied for 6 hours and removed. If selected as a dose regimen for Part B VP-102 will be applied for 6 hours and removed. In both parts, VP-102 is applied every 21 days for 4 treatments. |
| Part A: VP-102 24-hour Active | ACTIVE_COMPARATOR | For part A, VP-102 will be applied for 24 hours and removed. If selected as a dose regimen for Part B, VP-102 will be applied for 24 hours and removed. In both parts, VP-102 is applied every 21 days for 4 treatments. |
| Part A: Placebo | PLACEBO_COMPARATOR | For part A, VP-102 will be applied for 2-,6- or 24- hours and removed. Placebo is applied every 21 days for 4 treatments. |
| Part B & A: VP-102 6 hour-Active | ACTIVE_COMPARATOR | Part B, VP-102 will be applied for 6 hours and removed. VP-102 is applied every 21 days for 4 treatments. |
| Part B & A: 6-hour-Placebo | PLACEBO_COMPARATOR | Part B, Placebo will be applied for 6 hours and removed. VP-102 is applied every 21 days for 4 treatments. |
| Part B & A: VP-102 24-hour Active | ACTIVE_COMPARATOR | For part A, VP-102 will be applied for 24 hours and removed. If 24 hours is selected as a dose regimen for Part B, VP-102 will be applied for 24 hours and removed. VP-102 is applied every 21 days for 4 treatments. |
| Part B & A: 24-hour-Placebo | PLACEBO_COMPARATOR | Part B, VP-Placebo will be applied for 24 hours and removed. VP-102 is applied every 21 days for 4 treatments. |
| Name | Type | Description |
|---|---|---|
| VP-102 and applicator | COMBINATION_PRODUCT | In part A, VP-102 will be applied for either 2, 6 or 24 hours with each regimen compared to placebo. For part B, 2 of the regimens from part A will be chosen for Part B with each compared to Placebo. Only 4 arms are actually being studied. |
| Placebo | COMBINATION_PRODUCT | The placebo single-use applicator contains the same formulation as the VP-102 applicator but does not contain the active pharmaceutical ingredient cantharidin |
Key Inclusion Criteria: * Be healthy, immunocompetent males or females ≥ 18 years of age * Present with ≥ 2 and ≤ 30 external genital and/or perianal warts in ≥ 1 of the following anatomic areas: * In both sexes: medial thigh (except inguinal fold); supra-pubic, perineal, and perianal areas * ...
VP-102 is an investigational small molecule being developed by Verrica Pharmaceuticals Inc. (VRCA) for the treatment of molluscum contagiosum, condylomata acuminata (external genital warts), and common warts. It is currently in clinical development and has not been approved by the FDA.
VP-102 contains cantharidin, a topical agent that is applied directly to skin lesions. It is being studied for its effects on viral skin infections including molluscum contagiosum, external genital warts caused by human papillomavirus, and common warts.
VP-102 is developed by Verrica Pharmaceuticals Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol VRCA. The drug is also known as TO-208 in Japan.
VP-102 has completed Phase 2 trials for molluscum contagiosum and external genital warts. It is currently being evaluated in two Phase 3 trials for common warts, which are actively recruiting participants in the United States and Japan.
VP-102 has completed two Phase 2 trials: NCT03186378 in molluscum contagiosum and NCT03981822 in external genital warts. Two Phase 3 trials, NCT07246590 and NCT07637734, are currently recruiting for common warts, with a combined target enrollment of 600 participants.
Yes, VP-102 is also known as TO-208 in Japan. The drug is referred to as VP-102 in the United States and as VP-102/TO-208 internationally. Both names refer to the same cantharidin-based topical treatment.